Generic Name and Formulations:
Ixekizumab 80mg/mL; soln for SC inj; preservative-free.
Lilly, Eli and Company
Indications for TALTZ:
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Rotate inj site (eg, upper arms, thighs, or any quadrant of abdomen). ≥18yrs: 160mg (given as two 80mg SC injections) at Week 0, then 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.
<18yrs: not evaluated.
Increased risk of infections. If a serious infection develops, monitor closely and discontinue until resolves. Evaluate for TB infection and treat latent TB prior to initiating; monitor for active TB during and after therapy. Active TB infection: do not start. History of latent or active TB without confirmed adequate course of treatment: consider anti-TB therapy prior to initiation. Monitor for inflammatory bowel disease. Discontinue immediately and treat if a serious hypersensitivity reaction occurs. Complete all age appropriate immunizations based on current guidelines prior to initiating. Pregnancy. Nursing mothers.
Avoid concomitant live vaccines. Monitor CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine); consider dose adjustment of these substrates.
Inj site reactions, upper respiratory tract infections, nausea, tinea infections.
Single-use prefilled autoinjector—1, 2, 3; Single-use prefilled syringe—1, 2, 3